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OBJECTIVES The aim of this study was to evaluate the reproducibility of acute and chronic infarct size (IS)
by delayed enhancement (DE) magnetic resonance imaging (MRI).
BACKGROUND Infarct size measurements can be used as surrogate end point to reduce the sample size in
studies comparing different reperfusion strategies in myocardial infarction (MI). Delayed
enhancement MRI is a rather new technique, and so far infarct IS reproducibility has not
been established appropriately.
METHODS In 21 patients (10 acute MI and 11 chronic MI), IS was assessed repeatedly on consecutive
days by DE-MRI. Reproducibility, interobserver, and intraobserver variabilities were assessed
and compared by the Bland-Altman method.
RESULTS Acute and chronic IS were 17.1 19.6% (range 5.1% to 69.8%) of LV mass (%LV) and 16.9
9.9 %LV (range 2.0% to 36.0%), respectively. Infarct size difference (bias) between scan I and
scan II was0.5 %LV, and limits of agreement were2.4 %LV. Mean bias (0.7 %LV) and
limits of agreement (3.2%) were slightly higher for acute in comparison with chronic MI
with 0.4  1.3 %LV. Intraobserver and interobserver variability was low with a mean bias
of 0.3 %LV (limits of agreement  1.7 %LV) and 0.7 %LV (limits of agreement  2.2
%LV), respectively.
CONCLUSIONS Infarct size measurement by DE-MRI is an excellent tool for IS assessment, owing to its
excellent repeatability in chronic and acute MI. It has therefore the potential to serve as a
surrogate end point to uncover advantages of new reperfusion strategies. (J Am Coll Cardiol























Psing mortality as a primary study end point in studies
omparing different reperfusion strategies in acute myocar-
ial infarction (MI) requires increasingly large sample sizes
o test advances with existing therapies. Recently, there has
een growing interest in infarct size (IS) measurements as a
urrogate end point, allowing a much smaller sample size
ecause of its prognostic value (1). There are several methods
o assess IS, which include electrocardiography and imaging
rocedures such as single-photon emission computed tomog-
aphy (SPECT) and echocardiography or the indirect as-
essment by the release of cardiac enzymes (2). Each of
See page 1646
hese methods, however, has its limitations. By echocardi-
graphy, IS can be estimated indirectly only by evaluation of
eft ventricular (LV) ejection fraction, regional wall motion,
r end-systolic volumes (2). Single-photon emission computed
omography is hampered by attenuation artifacts and low
patial resolution, which does not allow for assessment of
mall infarcted areas (3). The measurement of cardiac
nzyme release is influenced by several factors, such as the
ariability of normal serum concentrations and the effects of
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ccepted November 16, 2005.oronary reperfusion (4), thus rendering each of these
ethods a suboptimal tool for IS assessment.
Delayed enhancement (DE) magnetic resonance imaging
MRI) allows the direct visualization of infarcted or necrotic
issue at very high spatial resolution and is increasingly used
o discriminate viable from non-viable myocardium (5–7). It
ay therefore be an optimal method to assess IS as
urrogate end point for studies comparing different reper-
usion strategies, if it can be assessed with low inter-study
eproducibility. However, so far reproducibility of DE-MRI
as been established only for chronic MI and for measure-
ent within one day without a second contrast agent
njection (2,8). The purpose of this trial was therefore to
ssess the reproducibility of acute and chronic IS measure-
ents in patients scanned at subsequent days with a second
ontrast agent injection.
ETHODS
tudy population. Ten patients with first acute MI (range
to 3 days after the index event) and 11 patients with
hronic MI (6 months) underwent two consecutive mag-
etic resonance scans on 2 consecutive days after written
nformed consent. All acute MI patients underwent primary
ercutaneous coronary intervention.
The study was approved by the local ethics committee.
atients were excluded from the study if they were hemo-
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Reproducibility of DE-MRI April 18, 2006:1641–5ations for magnetic resonance examination, such as pace-
akers and/or atrial fibrillation, among others. Furthermore,
atients were excluded if they had history of previous MI or
everal chronic MI.
RI. All patients were examined at rest in the supine
osition with a whole body 1.5-T MR scanner (Gyroscan
ntera CV, Philips Medical Systems, Best, the Netherlands)
quipped with a five-element cardiac phased-array coil for
ignal reception. A vectorcardiogram for gating and trigger-
ng was used. To define the orientation of the heart, a
eal-time interactive tool was applied. All images were
cquired during breath-hold at endexpiration. Delayed en-
ancement short axis images covering the whole ventricle
ere acquired at enddiastole approximately 15 min (range 9
o 27 min) after bolus injection (0.2 mmol/kg/bodyweight)
f Gadolinium-BOPTA (Gadovist, Schering, Germany). A
hree-dimensional inversion-recovery (IR) turbo gradient
cho sequence (repetition time 2.8 ms, echo time 1.1 ms,
ip angle 15°, typical spatial resolution 2.0  2.0  5 mm,
wo stacks, prepulse delay 175 to 300 ms) was used for
mage acquisition. The individual IR prepulse delay was
efined to obtain the maximal contrast between viable and
ecrotic myocardium. For the second MR examination, the
eart axes were newly defined by the interactive real-time
ool. The IR prepulse delay was also newly defined, and care
as taken to acquire DE images at the same time point after
ontrast injection.
mage analysis. Off-line image analysis was performed on
n independent workstation with dedicated software. Image
uality was assessed by a score ranging from 0 to 4 (0  not
ssessable; 4 optimal image quality). Left ventricular mass
as assessed for the DE images by tracing the endocardial
nd epicardial contours manually; papillary muscles were
ncluded. Once the myocardial contours were identified, IS
as determined by manual delineation of DE in each of the
hort axis images (Fig. 1). In patients with microvascular
bstruction these dark areas were included for IS analysis
9). Infarct size was expressed as percentage of LV volume,
iven by the sum of the volume of DE regions for all slices
ivided by the sum of the LV myocardial cross-sectional
olumes (%LV). All analyses were performed independently
ithout any reference to the prior or the next day’s images.
For assessment of interobserver variability in IS determi-
ation, the relevant datasets were analyzed by two indepen-
Abbreviations and Acronyms
DE  delayed enhancement
IR  inversion-recovery
IS  infarct size
LV  left ventricle/ventricular
MI  myocardial infarction
MRI  magnetic resonance imaging
%LV  percentage infarct size of left ventricular mass
SPECT  single-photon emission computed tomographyent observers. To determine intraobserver variability, anal- asis of all subjects was repeated after four weeks by one of
he observers without reviewing the results of the first
nalysis.
tatistical analysis. Continuous data are expressed as mean
D. The reproducibility of two measurements of the con-
ecutive scans, degrees of agreement between different
bservers, and repeated measurements of one observer were
etermined as mean absolute difference (bias) and 95%
onfidence interval of the mean difference (limits of agree-
ent) according to the methods of Bland and Altman (10).
ESULTS
he mean patient age was 59  12 years (range 39 to 80
ears); 17 patients were men, and 4 were women; 13
atients had anterior MI, and 8 had inferior MI. Image
uality was appropriate in all patients to assess IS. Mean
mage quality was 3.1  0.6 (range 2 to 4) for the DE
mages. In four acute MI patients, microvascular obstruction
as present.
Mean IS for the overall patient population was 17.0 
4.9 %LV. In patients with acute MI, mean IS was 17.1 
9.6 %LV (range 5.1 to 69.8); and in those with chronic
I, mean IS was 16.9  9.9 %LV (range 2.0 to 36.0).
able 1 summarizes technical parameters and MR IS of
cute and chronic MI in all patients.
eproducibility of MRI. Figure 2 shows the results of the
land-Altman repeatability analysis of all patients. The
verage difference in IS measurement between scan I and
can II was 0.5 %LV and the limits of agreement were
2.4 %LV. The mean bias (0.7%) and the limits of
greement (3.2 %LV) were slightly higher for acute in
omparison with chronic IS with 0.4  1.3 %LV. There
ere no systematic differences in IS between scan I and II
nd no differences for anterior and inferior MI.
nterobserver and intraobserver variability. Intraobserver
igure 1. Short axis slice showing the endocardial (green), epicardial
yellow), papillary (blue), and infarcted contours (white) in a patient with
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April 18, 2006:1641–5 Reproducibility of DE-MRImean bias of 0.3 %LV (limits of agreement 1.7 %LV)
nd 0.7 %LV (limits of agreement 2.2 %LV), respec-
ively (Figs. 3A and 3B).
ISCUSSION
he main finding of this study is that reproducibility of MR
S assessment measured at consecutive days is excellent for
cute and chronic anterior and inferior MI. In addition, the
ntraobserver and interobserver variability is low, making
RI the method of choice as a surrogate end point in
linical trials of reperfusion.
eproducibility of MRI. Currently, only limited trials
ave assessed the reproducibility of MRI for IS assessment.
ahrholdt et al. (8) acquired images at two different time







Scan I Scan II Sca
1 Acute  300 300 1
2 Acute  225 250 1
3 Acute  225 225 1
4 Acute  275 250 2
5 Chronic  250 250 1
6 Chronic  225 225 1
7 Acute  250 250 1
8 Acute  175 175 1
9 Acute  250 250 1
10 Acute  200 225 1
11 Chronic  300 300
12 Chronic  210 200 1
13 Chronic  225 225 1
14 Acute  225 225 1
15 Acute  225 225 1
16 Chronic  225 230 1
17 Chronic  275 300 2
18 Chronic  225 225 1
19 Chronic  225 225 1
20 Chronic  250 250 1
21 Chronic  200 200 1
V  left ventricle; MRI  magnetic resonance imaging; %LV  percentage infarc
igure 2. Bland-Altman reproducibility analysis for the overall patient
opulation. Central horizontal dotted line  mean absolute difference or
ias; upper and lower lines  95% confidence intervals (limits of













7 18 5.1 5.0 4.9 6.0
7 18 19.7 16.7 20.5 20.2
6 17 5.7 5.5 5.3 6.0
0 20 13.8 15.8 14.1 14.2
6 16 9.3 8.0 8.6 10.7
7 18 18.0 18.4 17.3 19.7
7 15 5.4 5.4 5.5 6.1
8 18 69.8 67.3 68.7 66.2
6 13 5.6 6.0 5.5 6.4
0 10 21.7 19.0 22.4 23.9
9 11 2.0 2.2 2.2 2.1
0 10 29.5 28.6 29.1 31.2
5 15 36.0 36.1 37.3 36.7
4 15 16.9 16.3 16.1 17.1
6 18 7.5 7.7 7.1 8.3
5 17 18.2 17.1 15.8 19.0
7 26 16.9 16.4 16.8 17.9
3 13 4.1 4.8 4.5 4.6
5 17 19.0 18.0 17.6 19.6
8 17 18.2 18.0 18.1 18.6
5 16 14.5 14.3 13.1 15.9iamonds  chronic MI. IS  infarct size; %LV  percentage of LV
olume.
a
Figure 3. Bland-Altman analysis for intraobserver (A) and interobserver
B) variability. Central horizontal dotted line  mean absolute difference
r bias; upper and lower lines  95% confidence intervals (limits of
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Reproducibility of DE-MRI April 18, 2006:1641–5oints (10 and 27 min). Their reproducibility data were
imilar to the current trial with a mean bias of 0.1 (limits
f agreement 2.4 %LV); however, this trial was restricted
o chronic infarctions and to image acquisition after injec-
ion of a single contrast agent bolus. In another trial, 10
atients with chronic MI underwent repeated IS measure-
ent 2 months apart. The apparent IS was not statistically
ifferent between the paired studies, although bias and
imits of agreement were not reported (11). Therefore, the
urrent trial is the first trial that assessed reproducibility in
he acute and chronic MI setting with measurement at
onsecutive days with appropriate statistical methods.
ccurate infarct sizing by MRI. Another important factor
esides reproducibility is the accuracy of infarct sizing. This
an be affected by several factors. First, the time interval
etween contrast agent injection and image acquisition
nfluences IS, if constant IR times (time between inversion
repulse and image acquisition) are used (12). Recent
tudies have shown, however, that by using appropriate
nversion times to null normal myocardium, the time
etween contrast injection and image acquisition does not
nfluence IS (8,13,14). Therefore, we prospectively designed
he scan protocol to minimize inconsistent timing and used
he best validated IR method (15), which was individually
dapted to null normal myocardium in each patient and in
ach scan.
Image analysis is a crucial point for accurate IS assess-
ent. Most studies have used arbitrary criteria for the defini-
ion of infarcted tissue. In some trials manual tracing of the
nhanced region was performed (7,12), whereas in other trials
emi-automatic computer-assisted algorithms were used
8,13,14,16). Recently, the most objective technique has been
efined by the full-width at half-maximum criterion (13).
his approach compared better with manual tracing and
ith an SD technique, which included hyperenhanced
ixels with image intensities 1 to 6 standard deviations
bove the mean image intensity of remote myocardium (13).
evertheless, manual tracing used in our study, which
ight be affected by subjective window setting, showed
xcellent repeatability results. These might even have been
etter by the use of the full-width at half-maximum
riterion.
Furthermore, we had full volumetric coverage by using a
hree-dimensional IR sequence with two stacks acquired
ith two breath-holds. This minimizes chances of registra-
ion errors, which are inherent to a two-dimensional se-
uence acquiring each slice with a single breath-hold (17).
Delayed enhancement occurs in areas of expanded extra-
ellular space, owing to slower distribution kinetics and
igher regional Gadolinium concentration compared with
ormal myocardium. The theoretical pathologic basis in
hronic MI is a result of fibrosis with subsequent increased
xtracellular space, whereas in acute MI, expansion of extra-
ellular volume is deemed to be due to myocyte membrane
isruption and increased capillary permeability (18). This
ifferent pathophysiological basis might explain the slightly better reproducibility in chronic compared with acute MI.
n addition, the extent of microvascular obstruction, another
apidly changing factor in acute MI, might have influenced
he IS reproducibility (19); however, because microvascular
bstruction usually occurs in the subendocardial zone and
ecause these areas have been included for IS analysis, this
nfluence might be negligible.
nfarct size end point use in clinical trials. Single-photon
mission computed tomography IS imaging has been used
xtensively as surrogate end point in clinical trials (2). An
mportant advantage of SPECT is the ability to assess either
alvaged myocardium by measuring both the acute and the
nal perfusion defect or the final IS. In contrast to the
xtensive experience with SPECT, to date there is only
imited experience with use of DE-MRI as an end point in
linical trials. One early observational and one randomized
tudy, using older imaging sequences, reported IS for patients
ith different reperfusion strategies in MI (20,21). Currently,
here is only one randomized clinical trial using state-of-the-art
R sequences (22).
As a consequence of the limited use of DE-MRI, there
re only very limited prognostic data in fewer than 50
atients (9). In this trial, patient outcome for a combined
linical end point was associated with the extent of final IS.
urthermore, MR infarct sizing is limited by non-
tandardized acquisition protocols and non-standardized
uantitation. Therefore, multicenter comparability trials have
ot been performed thus far; however, owing to the high
patial resolution with ability to detect even very small
ubendocardial infarcts (23), more widespread availability in
he future, and easier imaging protocols, these obstacles
ight be able to be overcome.
ample size calculation. The reproducibility of an imag-
ng procedure has practical implications for the sample size
f clinical trials using IS as surrogate end point. The
nfluence of measurement reproducibility is a function of the
statistic (24), which means that the number of patients
equired is proportional to the square of the standard
eviation of the imaging end point as shown for SPECT
25). If IS is used as end point to show a change with a
ower of 90% and an alpha-error of 0.05, sample size
alculations showed that (using the 1.2% standard deviation
0.5 limits of agreement] of MRI reproducibility in com-
arison with 4% standard deviation [0.5 limits of agree-
ent] for recently published reproducibility data [8]) the
equired patient number can be reduced by 80% to 91%,
epending on the expected absolute change in IS. This
alculation, however, is made on the basis of a comparison
ith historical SPECT data, limited number of patients,
nd on the assumption that no other factors play a role in
ample size calculation.
tudy limitations. As a result of exclusion of patients with
previous MI and patients with atrial fibrillation, IS assess-
ent was rather non-complex. Inclusion of patients with
revious MI might have led to an impaired reproducibility,
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April 18, 2006:1641–5 Reproducibility of DE-MRIe more difficult. Furthermore, atrial fibrillation might
mpair image quality. Therefore, the current reproducibility
ata cannot be generalized to the entire population of
atients with MI.
onclusions. Infarct size measurement by DE-MRI is an
xcellent tool for acute and chronic MI owing to its high
eproducibility and low intraobserver and interobserver vari-
bility. In comparison with other imaging modalities, it might
llow a further sample size reduction and has therefore the
otential to serve as a surrogate end point to uncover advan-
ages of new reperfusion strategies in acute MI.
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